|
|
|
12.01.26 - 17:01
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 1/2026
12 January 2026
Reykjavik, Iceland/Copenhagen, Denmark, 12 January 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025.
During the period 5 January to 9 January 2026 Embla Medical has acquired 41,000 shares under the Program at the average price of DKK 32.37. Following the transactions below, the Company holds 2,709,596 shares, corresponding to 0.63% of the...
|
|
|
09.01.26 - 07:00
|
Embla Medical hf: Conference call details for Q4/FY 2025 (Cision)
|
|
|
Reykjavik, Iceland/Copenhagen, Denmark, 9 January 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q4/FY 2025 Report on February 3, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST.
The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English.
Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors
To participate...
|
|
|
23.12.25 - 17:30
|
Embla Medical hf: Initiating New Share Buyback Program (Cision)
|
|
|
Announcement no. 61/2025
23 December 2025
Reykjavik, Iceland/Copenhagen, Denmark, December 23, 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the Company has decided to initiate a new share buyback program (the “Program”) on Monday, 5 January 2026.
The Program will be carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission's delegated regulation 2016/1052. The purpose of the Program is to reduce the Company's...
|
|
|
23.12.25 - 17:00
|
Embla Medical hf: Share Buyback Program Completed (Cision)
|
|
|
Announcement no. 60/2025
23 December 2025
Reykjavik, Iceland/Copenhagen, Denmark, 23 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced the completion of the share buyback program, which was announced in Company Announcement no. 3/2025 dated 7 February 2025. Following are the last transactions carried out under the current share buyback program.
Transaction No. of Avg. purchase price in DKK Transaction value in DKK
date shares
22 December 5,000 33.70...
|
|
|
22.12.25 - 17:00
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 59/2025
22 December 2025
Reykjavik, Iceland/Copenhagen, Denmark, 22 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 15 December to 19 December 2025 Embla Medical has acquired 10,400 shares under the Program at the average price of DKK 33.20. Following the transactions below, the Company holds 2,668,596 shares, corresponding to 0.62% of...
|
|
|
15.12.25 - 17:06
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 58/2025
15 December 2025
Reykjavik, Iceland/Copenhagen, Denmark, 15 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 8 December to 12 December 2025 Embla Medical has acquired 45,275 shares under the Program at the average price of DKK 36.34. Following the transactions below, the Company holds 2,658,196 shares, corresponding to 0.62% of...
|
|
|
12.12.25 - 17:06
|
Embla Medical: Financial Calendar 2026 (Cision)
|
|
|
Announcement no. 57/2025
Reykjavik, Iceland/Copenhagen, Denmark, December 12, 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today published its financial calendar for 2026.
Financial Calendar 2026
3 February 2026 Interim Report Q4 2025/2025 Annual Report
10 March 2026 2026 Annual General Meeting
28 April 2026 Interim Report Q1 2026
21 July 2026 Interim Report Q2 2026
20 October 2026...
|
|
|
08.12.25 - 17:01
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 56/2025
8 December 2025
Reykjavik, Iceland/Copenhagen, Denmark, 8 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 1 December to 5 December 2025 Embla Medical has acquired 30,000 shares under the Program at the average price of DKK 36.90. Following the transactions below, the Company holds 2,618,929 shares, corresponding to 0.61% of the...
|
|
|
01.12.25 - 17:01
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 55/2025
1 December 2025
Reykjavik, Iceland/Copenhagen, Denmark, 1 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 24 November to 28 November 2025 Embla Medical has acquired 30,000 shares under the Program at the average price of DKK 34.52. Following the transactions below, the Company holds 2,588,929 shares, corresponding to 0.60% of...
|
|
|
24.11.25 - 17:00
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 54/2025
24 November 2025
Reykjavik, Iceland/Copenhagen, Denmark, 24 November 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 17 November to 21 November 2025 Embla Medical has acquired 23,456 shares under the Program at the average price of DKK 33.41. Following the transactions below, the Company holds 2,558,929 shares, corresponding to 0.59% of...
|
|
|
17.11.25 - 17:00
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 53/2025
17 November 2025
Reykjavik, Iceland/Copenhagen, Denmark, 17 November 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 10 November to 14 November 2025 Embla Medical has acquired 37,538 shares under the Program at the average price of DKK 34.53. Following the transactions below, the Company holds 2,538,022 shares, corresponding to 0.59% of...
|
|
|
10.11.25 - 17:02
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 52/2025
10 November 2025
Reykjavik, Iceland/Copenhagen, Denmark, 10 November 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 3 November to 7 November 2025 Embla Medical has acquired 50,692 shares under the Program at the average price of DKK 34.29. Following the transactions below, the Company holds 2,500,484 shares, corresponding to 0.58% of...
|
|
|
|
|
03.11.25 - 17:06
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 51/2025
3 November 2025
Reykjavik, Iceland/Copenhagen, Denmark, 3 November 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 27 October to 31 October 2025 Embla Medical has acquired 59,000 shares under the Program at the average price of DKK 33.79. Following the transactions below, the Company holds 2,449,792 shares, corresponding to 0.57% of the...
|
|
|
27.10.25 - 17:06
|
Embla Medical hf: Transactions in relation to Share Buyback Program (Cision)
|
|
|
Announcement no. 50/2025
27 October 2025
Reykjavik, Iceland/Copenhagen, Denmark, 27 October 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 20 October to 24 October 2025 Embla Medical has acquired 50,000 shares under the Program at the average price of DKK 32.65. Following the transactions below, the Company holds 2,397,313 shares, corresponding to 0.56% of the...
|
|
|
|
|
|
|
21.10.25 - 07:42
|
Embla Medical hf: Interim Report Q3 2025 (PR Newswire)
|
|
|
COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire/ -- Announcement no. 49/2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: "Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in......
|
|
|
21.10.25 - 07:33
|
Embla Medical hf: Interim Report Q3 2025 (PR Newswire)
|
|
|
COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire/ -- Announcement no. 49/2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: "Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in......
|
|
|
21.10.25 - 07:00
|
Embla Medical hf: Interim Report Q3 2025 (Cision)
|
|
|
Announcement no. 49/2025
Interim report Q3 2025
21 October 2025
Sveinn Sölvason, President and CEO, comments:
“Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched innovations such as Navii, Icon, and Pro-Flex Terra.
Sales in our Bracing & Supports and Patient Care...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
